Abstract Library

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Bartsch D, Albers M, Bollmann C, Roth S,

Keywords: chemoprevention, neuroendocrine neoplasms, somatostatin analogue ,

#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors

Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Fendrich V

Authors: Fendrich V, Manoharan J, Lopez C, Waldmann J, Bartsch D,

Keywords: neuroendocrine pancreatic tumors, aspirin, chemoprevention,